Stella Pharma Corporation

¥345.00As of Sun 8 Nov 2026, 12:00 UTC
TSE:4888Healthcare
Country Japan
PE (Fwd) •••
TSR 6Y CAGR (8.25%)
Div yield —
ROE (27.19%)
Biotechnology
Beta (5Y) 0.30
PE TTM —
TSR TTM 9.52%
Mkt cap ¥13.12B
ROIC (13.34%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥355
2.87%
(60.22%)
Buy 11|5|7|5|0
3Q26
4Q26
1Q27
2Q27
Earnings per share¥
9.67
9.37
9.72
9.24
29.01%
11.99%
11.76%
(2.12%)
Revenue¥B
1.096
1.104
1.071
1.040
9.78%
7.94%
(1.01%)
(5.25%)
Peers (US$83.31M)
Cap (US$)
PE
94.71M
90.59x
83.60M
—
Capital
TTM
5Y
10Y
Leveragex
0.537
—
—
EBIT/Intx
1.049
0.139
0.138
Own earn%
7.55
285.68
221.56
Sh yield%
51.83
5.05
4.85
Owners
Insiders/Inst%
2.34
23.35
Short interest%
1.30
SBC / revenue%
1.52
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
5–10
$1 testx
—
Incr. ROIC%
43